Breaking News, Promotions & Moves

Biogen Appoints ALS Innovation Hub VP

Johns to lead new unit dedicated to development of novel ALS therapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Donald R. Johns, M.D., has been named vice president of Biogen Idec’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new unit dedicated to accelerating the discovery and development of novel ALS therapies, integrating research with clinical development. Dr. Johns reports to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer. Dr. Johns will lead a group with expertise that spans translational science and technology, neurology research, experimen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters